Cases of the autoimmune skin condition eczema appear to rise in areas most plagued by air pollution, new research show ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Enveda Therapeutics Inc. has received U.S. IND clearance and advanced into phase I trials with ENV-294, its naturally derived anti-inflammatory.

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good afternoon, everyone, and thank you for standing by, and ...

Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United States. ZORYVE cream 0.15% was approved by the FDA for the ...

Enveda, a biotechnology company using AI to translate nature into new medicines, announced today that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing CohortInterim Data from Atopic Dermatitis Trial ...

Parents of children with atopic dermatitis (AD, also called eczema) know that the allergic condition can ... "Elimination diets aren't recommended as a treatment for AD, according to guidelines from ...

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, announced today its engagement in a collaboration with the SKIN Research ...

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.